Your shopping cart is currently empty

CD532 is A highly potent Aurora A kinase inhibitor with an IC50 value of 45 nM. CD532 can block Aurora A kinase activity, drive MYCN degradation, and can directly interact with AURKA and induce global conformational transformation. CD532 can be used to study cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $33 | In Stock | In Stock | |
| 5 mg | $76 | In Stock | In Stock | |
| 10 mg | $122 | In Stock | In Stock | |
| 25 mg | $239 | In Stock | In Stock | |
| 50 mg | Inquiry | In Stock | In Stock |
| Description | CD532 is A highly potent Aurora A kinase inhibitor with an IC50 value of 45 nM. CD532 can block Aurora A kinase activity, drive MYCN degradation, and can directly interact with AURKA and induce global conformational transformation. CD532 can be used to study cancer. |
| Targets&IC50 | SK-N-BE cells:223.2 nM(EC50), Kelly:146.7 nM(EC50), Aurora A:45 nM |
| In vitro | In MYCN-amplified neuroblastoma cell lines SK-N-BE(2) and Kelly, CD532 (1-10000 nM; 72 h) exhibits cytotoxicity with EC50s of 223.2 nM and 146.7 nM, respectively[1]. In SK-N-BE(2) cells, CD532 (0.1-1 μM; 24 h) causes a dose-dependent loss of MYCN protein[1]. Furthermore, CD532 (1 μM; 6 h) prevents S-phase entry in SK-N-BE(2) cells[1]. |
| In vivo | In mice with subcutaneous sonic hedgehog (SHH)-subtype medulloblastoma, CD532 (25 mg/kg; i.p. twice weekly for 3 weeks) decreases the tumor volume and increases survival[1]. In MYCN-amplified neuroblastoma xenografts, CD532 (60 mg/kg; i.p. for 2 days) reduces the level of MYCN protein[1]. CD532 (20 mg/kg; i.p.) in mice exhibits a serum half-life of ~1.5 hours and an AUC0-24 of 27 μM•h[1]. |
| Molecular Weight | 522.52 |
| Formula | C26H25F3N8O |
| Cas No. | 1639009-81-6 |
| Smiles | N(C=1C=C(NN1)C2CCCC2)C3=NC(NC4=CC=C(NC(NC5=CC(C(F)(F)F)=CC=C5)=O)C=C4)=NC=C3 |
| Relative Density. | 1.464 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (287.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.57 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.